Revolutionizing Healthcare: How Bioengineering & Stem Cells Are Transforming The Future Of Medicine

Can bioengineering improve the health, vitality, and longevity of human beings? What would the future look like if the medical system were about preserving health rather than just treating symptoms? In this episode, Kevin Caldwell, the CEO, Co-Founder, and President of Ossium Health, sits down to share his thoughts… Ossium Health is a commercial-stage bioengineering company that uses its exclusive organ donor bone marrow banking platform to develop stem cell therapies for patients suffering from life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Initially built from a small startup, it evolved into the clinical-stage bioengineering company it is today with one primary mission: To improve human health through bioengineering. Join the conversation now to explore:   ●      How Kevin’s mindset shift in business led to the creation of Ossium. ●      Why the healthcare system isn’t adequately equipped to deal with modern chronic diseases. ●      Types of cell therapies that provide relief for patients with blood and immune conditions. ●      The role that cell composition plays in the reactivity between donors and recipients.  Before founding Ossium, Kevin worked as an Engagement Manager at McKinsey’s San Francisco office, where he advised clients in the biotechnology and healthcare industries. His projects spanned from conducting due diligence on biotech startup acquisitions to restructuring financially distressed biopharma companies. Over the course of his tenure, Kevin led more than 20 engagements for over a dozen clients, guiding teams in strategies for revenue growth, market-entry, and organizational restructuring. To learn about Kevin’s cutting-edge work with Ossium Health, visit their website now!  🎧 Listen now on Apple Podcasts: http://apple.co/30PvU9C